Atani is a specialty pharmaceutical company that focuses on delivering needed cancer drugs to the underserved Japanese market. Atani exerts world-class expertise to successfully bring these drugs to market based on its ability to:

• IDENTIFY the best product candidates through our structured licensing process;
• Clinically DEVELOP and COMMERCIALIZE these products.

Atani’s strategic partner for product development and commercialization is Quintiles Transnational, the world’s leading pharmaceutical services organization. Quintiles has helped develop or commercialize each of the world’s top-30 best selling drugs each year since 2001.

Founded in 2006 by an international management team with deep experience in the Japanese market, Atani leverages its broad cross-cultural experience and best practices to increase access to important new cancer drugs in Japan, thereby helping to improve patients’ lives.